Floatz logo

cd19-cart

Follicular Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyEarly Phase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

210 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

cd19-cart is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
C
Indicative ·
36 / 100
View asset →
mantle cell lymphomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →